Neoadjuvant PD-1 blockade in resectable lung cancer

New England Journal of Medicine

Volumn 378, Issue 21, 2018, Pages 1976-1986

  Forde, Patrick M ^a   Chaft, Jamie E ^b   Smith, Kellie N ^a   Anagnostou, Valsamo ^a   Cottrell, Tricia R ^a   Hellmann, Matthew D ^b   Zahurak, Marianna ^a   Broderick, Stephen ^a   Yang, Stephen C ^a   Jones, David R ^b   Battafarano, Richard J ^a   Velez, Moises J ^b   Rekhtman, Natasha ^b   Olah, Zachary ^b   Verde, Franco ^a   Naidoo, Jarushka ^a   Marrone, Kristen A ^a   Guo, Haidan ^a   Sidhom, John William ^a   Zhang, Jiajia ^a   Caushi, Justina X ^a   Chan, Hok Yee ^a   Scharpf, Robert B ^a   White, James ^a   Gabrielson, Edward ^a   Wang, Hao ^a   Rosner, Gary L ^a   Rusch, Valerie ^b   Wolchok, Jedd D ^b,c,d,e   Merghoub, Taha ^b,c,d,e   Taube, Janis M ^a   Velculescu, Victor E ^a   Topalian, Suzanne L ^a   Brahmer, Julie R ^a   Pardoll, Drew M ^a   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Ludwig Collaborative   (United States)

^d PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY   (United States)

^e Swim Across America Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CANCER SURGERY; CELL CLONING; CLINICAL ARTICLE; CORRELATIONAL STUDY; DISEASE BURDEN; DRUG EFFECT; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; GENE MUTATION; HUMAN; MALE; MULTICENTER STUDY; NEOADJUVANT THERAPY; NON SMALL CELL LUNG CANCER; PILOT STUDY; PNEUMONIA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BIOPSY; CLINICAL TRIAL; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; PILOT PROJECTS;

EID: 85047781450     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1716078     Document Type: Article

References (32)

1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
2. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced nonsmall- cell lung cancer. J Clin Oncol 2015; 33: 2004-12.
3. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated nonsmall- cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389: 255-65.
4. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-smallcell lung cancer. N Engl J Med 2016; 375: 1823-33.
5. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377: 1919-29.
6. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non- small-cell lung cancer. N Engl J Med 2015; 372: 2018-28.
7. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J Thorac Oncol 2007; 2: 706-14.
8. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-9.
9. Wakelee HA, Dahlberg SE, Keller SM, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2017; 18: 1610-23
10. McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351: 1463-9.
11. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
12. Revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 for adverse event reporting (https://ctep.cancer.gov/protocoldevelopment/electronic-applications/ctc.htm#ctc-40).
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47
14. Pataer A, Kalhor N, Correa AM, et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 2012; 7: 825-32.
15. Hellmann MD, Chaft JE, William WN Jr, et al. Pathological response after neoadjuvant chemotherapy in resectable nonsmall- cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 2014; 15(1): e42-e50.
16. Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 2016; 374: 2542-52.
17. Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med 2015; 7: 283ra53.
18. Anagnostou V, Smith KN, Forde PM, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov 2017; 7: 264-76.
19. Giraldo NA, Kaunitz GJ, Cottrell TR, et al. The differential association of PD-1, PD-L1, and CD8+ cells with response to pembrolizumab and presence of Merkel cell polyomavirus (MCPyV) in patients with Merkel cell carcinoma (MCC). Cancer Res 2017; 77: 662. abstract.
20. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra37.
21. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-25.
22. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-8.
23. Srivastava SK, Robins HS. Palindromic nucleotide analysis in human T cell receptor rearrangements. PLoS One 2012; 7(12): e52250.
24. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-71.
25. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409-13.
26. Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016; 34: 1510-7.
27. Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res 2009; 15: 7116-8.
28. Liu J, Blake SJ, Yong MC, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov 2016; 6: 1382-99.
29. Salmon H, Idoyaga J, Rahman A, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 2016; 44: 924-38.
30. Goldberg MV, Maris CH, Hipkiss EL, et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 2007; 110: 186-92.
31. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-20
32. Chaft JE, Rusch V, Ginsberg MS, et al. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. J Thorac Oncol 2013; 8: 1084-90.